Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GNLX
GNLX logo

GNLX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Genelux Corp (GNLX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.960
1 Day change
-0.34%
52 Week Range
8.540
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Genelux Corp (GNLX) is not a good buy right now for a beginner with a long-term focus and $50,000-$100,000 to deploy. The stock lacks strong bullish confirmation, has no recent news catalyst, no meaningful insider/hedge fund accumulation, and no proprietary buy signal. While the options positioning looks bullish, the broader technical setup is still weak, so the best direct opinion is to hold off on buying now.

Technical Analysis

The current trend is mixed to weak. MACD histogram is slightly negative and contracting, which indicates momentum is not turning up convincingly. RSI_6 at 57.58 is neutral, showing no clear overbought or oversold edge. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, suggesting the stock remains in a longer-term downtrend or weak recovery phase. Price at 3.005 is just above the pivot (2.934) and below R1 (3.049), so it is trading near short-term decision levels rather than breaking out. Overall, the technical picture does not support an aggressive long-term entry right now.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment appears bullish on balance. The open interest put-call ratio of 0.02 is extremely low, showing calls dominate puts. The option volume put-call ratio of 0.5 also leans bullish. However, absolute activity is still modest, and the implied volatility is extremely high at 872 with IV rank 86.09 and IV percentile 90.87, meaning options are pricing in very large expected moves. That supports speculative bullish sentiment, but it does not override the weak technical setup for a beginner long-term investor.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
6

Positive Catalysts

  • ["Options positioning is strongly call-skewed, suggesting bullish sentiment among traders.", "Price is slightly above the pivot level, so there is at least some short-term stabilization.", "Analyst/market flow data is not negative, and there is no reported recent selling pressure from insiders or hedge funds."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst.", "Hedge funds are neutral with no significant accumulation trend.", "Insiders are neutral with no notable buying support.", "Technical trend remains bearish with SMA_200 > SMA_20 > SMA_5.", "MACD remains below zero and contracting, showing weak momentum.", "No AI Stock Picker signal today and no recent SwingMax signal."]

Financial Performance

No usable latest-quarter financial snapshot was provided because of a data error, so there is no reliable quarter-by-quarter growth assessment available. The latest quarter season could not be identified from the supplied data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no recent Wall Street upgrade/downgrade trend to report. Based on the available evidence, Wall Street pros appear neutral at best: there is no visible consensus bullish catalyst, while the technical trend and lack of news argue against a strong buy view.

Wall Street analysts forecast GNLX stock price to rise
4 Analyst Rating
Wall Street analysts forecast GNLX stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.970
sliders
Low
16
Averages
22.5
High
31
Current: 2.970
sliders
Low
16
Averages
22.5
High
31
Benchmark
Speculative Buy
downgrade
$23 -> $20
AI Analysis
2026-03-20
Reason
Benchmark
Price Target
$23 -> $20
AI Analysis
2026-03-20
downgrade
Speculative Buy
Reason
Benchmark lowered the firm's price target on Genelux to $20 from $23 and keeps a Speculative Buy rating on the shares after adjusting the firm's sum-of-the-parts analysis for the new share count and moving the peak year assumption to 2033.
H.C. Wainwright
H.C. Wainwright
maintain
$31
2026-01-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$31
2026-01-05
maintain
Reason
Genelux reported updated interim data showing IV Olvi-Vec plus platinum chemotherapy achieved a 33% overall response rate and 67% disease control rate in heavily pretreated platinum-relapsed/refractory lung cancer patients, outperforming historical response rates, with notable tumor shrinkage and signals of a dose-response effect at higher dosing, H.C. Wainwright tells investors in a research note. Early durability signals, including progression free survival extending to 12.1 months in one case despite single-cycle dosing and no maintenance therapy, suggest potential activity in overcoming platinum resistance, with further data expected in 2026, the firm says. H.C. Wainwright has a Buy rating and $31 price target on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GNLX
Unlock Now

People Also Watch